MS Bio jumps 73% on KOSDAQ debut after $23.5M IPO
What's the deal? MS Bio, a South Korean regenerative medicine company, surged more than 70% above its offering price on its KOSDAQ trading debut on October 22. Shares traded at US$11.3 shortly after the open, up 73.33% from the 7,800-won offer price. The IPO raised roughly US$26.2M (about $23.5 million, FX-converted).
Why now? MS Bio drew unusually strong appetite ahead of listing. Its retail subscription ran at 1,538-to-1, pulling in about US$5.03B in deposits, and the offer priced at the top of its range. Institutional demand ran at 1,096-to-1, with KB SecuritiesDealroom has a profile for this one. Try Dealroom → underwriting the deal.
By the numbers: The company is also profitable. Operating profit rose about 42.9% last year to US$7.18M, from US$5.02M a year earlier, driven by production efficiency gains and expanded supply.
What's the endgame? Founded in 2015, MS Bio develops human tissue implants and medical devices for tissue regeneration and repair. It plans to use the proceeds to build a new plant in Ochang, North Chungcheong Province, expand into the US and Vietnam, and fund clinical trials.
What could go wrong? The open question is whether the debut premium holds. A strong first day fits a recent KOSDAQ pattern of volatile trading: AI infrastructure firm Elice fell about 32% on its debut two days earlier, despite heavy subscription demand of its own.
The signal: MS Bio's pop ends a months-long drought in South Korea's IPO market, which has turned busy again with a string of KOSDAQ listings. Its combination of profits and concrete expansion plans gives it a more grounded story than a purely speculative listing — but investors will judge the shares on execution, not subscription enthusiasm.
Read more: chosun.com
Image credit: Generated with Gemini
